- Home
- MYGN vs SES Comparison
MYGN vs SES Comparison
Compare MYGN & SES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MYGN | SES |
|---|---|---|
| Founded | 1991 | 2012 |
| Country | United States | United States |
| Employees | N/A | 215 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.6M | 399.6M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | MYGN | SES |
|---|---|---|
| Price | $4.42 | $1.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $7.64 | $4.00 |
| AVG Volume (30 Days) | 1.7M | ★ 9.3M |
| Earning Date | 05-05-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $771,400,000.00 | N/A |
| Revenue This Year | $6.89 | $53.90 |
| Revenue Next Year | $5.35 | $111.26 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.33 | N/A |
| 52 Week Low | $3.76 | $0.42 |
| 52 Week High | $8.63 | $3.73 |
Technical Indicators
Market Signals| Indicator | MYGN | SES |
|---|---|---|
| Relative Strength Index (RSI) | 38.72 | 30.76 |
| Support Level | $4.24 | $0.82 |
| Resistance Level | $5.69 | $1.22 |
| Average True Range (ATR) | 0.31 | 0.07 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 3.87 | 10.26 |
Price Performance
Historical ComparisonAbout MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
About SES SES AI Corporation
SES AI Corp is a developer and manufacturer of rechargeable battery technologies and battery materials for Energy Storage Systems (ESS), Urban Air Mobility (UAM), drones, robotics, electric vehicles (EVs), and other applications. For Enery Storage Systems, the company supplies hardware and software solutions with battery health and safety management software powered by its AI-based platform, Molecular Universe. Additionally, it offers battery materials and high-energy and power-density Li-Metal and Li-ion cells, which can be used for drones, UAM, robotics, and EV applications. The company also offers access to Molecular Universe as a software product. Currently, it generates maximum revenue from the development of Li-ion and Li-Metal battery materials as per the client's specifications.